Blueprint Medicines Corp (NASDAQ:BPMC) was up NaN during mid-day trading on Wednesday . The stock traded as high as $72.49 and last traded at $0.00. Approximately 711,348 shares were traded during trading, an increase of Infinity from the average daily volume of 0 shares.

Several equities research analysts have recently issued reports on BPMC shares. Canaccord Genuity reissued a “buy” rating and set a $56.00 price objective on shares of Blueprint Medicines Corp in a research report on Monday, September 11th. DA Davidson started coverage on shares of Blueprint Medicines Corp in a research report on Friday, September 29th. They set a “buy” rating and a $90.00 price objective for the company. Zacks Investment Research raised shares of Blueprint Medicines Corp from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Wedbush reissued an “outperform” rating and set a $66.00 price objective on shares of Blueprint Medicines Corp in a research report on Tuesday, August 22nd. Finally, BidaskClub downgraded shares of Blueprint Medicines Corp from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 19th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $68.69.

Blueprint Medicines Corp (NASDAQ:BPMC) last announced its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.06). The business had revenue of $8.07 million for the quarter, compared to the consensus estimate of $5.35 million. Blueprint Medicines Corp had a negative net margin of 567.27% and a negative return on equity of 47.67%. The business’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.62) EPS.

In other Blueprint Medicines Corp news, insider Kate Haviland sold 5,449 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $66.44, for a total transaction of $362,031.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Anthony L. Boral sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $48.60, for a total transaction of $243,000.00. Following the sale, the insider now owns 5,000 shares of the company’s stock, valued at approximately $243,000. The disclosure for this sale can be found here. Insiders have sold a total of 69,305 shares of company stock valued at $3,606,782 in the last 90 days. 3.40% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in BPMC. Wells Fargo & Company MN increased its stake in Blueprint Medicines Corp by 40.2% during the 1st quarter. Wells Fargo & Company MN now owns 21,928 shares of the biotechnology company’s stock valued at $877,000 after purchasing an additional 6,286 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Blueprint Medicines Corp by 29.0% during the 1st quarter. Bank of New York Mellon Corp now owns 120,568 shares of the biotechnology company’s stock valued at $4,822,000 after purchasing an additional 27,095 shares in the last quarter. UBS Asset Management Americas Inc. bought a new stake in Blueprint Medicines Corp during the 1st quarter valued at $201,000. Parametric Portfolio Associates LLC bought a new stake in Blueprint Medicines Corp during the 1st quarter valued at $375,000. Finally, Prudential Financial Inc. increased its stake in Blueprint Medicines Corp by 6.0% during the 1st quarter. Prudential Financial Inc. now owns 17,304 shares of the biotechnology company’s stock valued at $692,000 after purchasing an additional 984 shares in the last quarter. Institutional investors and hedge funds own 90.64% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Blueprint Medicines Corp (BPMC) Trading Up NaN” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://theolympiareport.com/2017/11/01/blueprint-medicines-corp-bpmc-trading-up-nan.html.

Blueprint Medicines Corp Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Receive News & Ratings for Blueprint Medicines Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.